Core Viewpoint - The announcement reveals that the controlling shareholder of Zhendong Pharmaceutical, Zhendong Group, has pledged 7.32 million shares of the company, which accounts for 2.42% of its holdings and 0.73% of the total share capital of the company [1] Summary by Relevant Categories Share Pledge Details - The pledge started on July 17, 2025, and the purpose of the pledge is for the group's own production and operation [1] - After this pledge, Zhendong Group has cumulatively pledged 200 million shares, representing 66.08% of its holdings and 19.86% of the total share capital of the company [1]

本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"或"本公司"）于 近日接到控股股东山西振东健康产业集团有限公司（以下简称"振 东集团"）通知，获悉其所持有的本公司部分股份做了质押，具体 事项如下： 证券代码：300158 证券简称：振东制药 公告编号：2025-035 山西振东制药股份有限公司 关于股东股份质押的公告 截至公告披露日，上述股东所持质押股份情况如下： | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 占其 | 占公 | 情况 | | 情况 | | | 股东 | 持股 | 持股 | 本次质押 | 本次质押 | 所持 | 司总 | 已质押 | | | | | 名称 | 数量 | 比例 | 前质押股 | 后质押股 | 股份 | 股本 | 股份限 | | 未质押股 | 占未质 | | | | | 份数量 | 份数量 | 比例 | 比例 ...

2025 年 1 月 24 日，公司收到仲裁委员会仲裁庭送达的《（2025） 中国贸仲京裁字第 0227 号裁决书》（以下简称"裁决书"），根据 仲裁结果，公司需向朗迪公司支付人民币 5 亿元。公司支付完毕全部 款项后，双方之间与《药品委托生产合同》及其补充合同相关的所有 争议（包括 DE20242588 号案本请求及反请求下的全部争议，及其他 任何潜在的求偿或主张）即全部解决，《股权出售协议》相关所有争 议亦全部解决，任何一方不得再以任何理由就前述争议向对方提起诉 讼/仲裁或其他权利主张。具体内容详见公司于 2025 年 1 月 24 日在 巨潮资讯网(http://www.cninfo.com.cn)上披露的《关于公司重大仲裁事 项进展的公告》（公告编号：2025-005）。 证券代码：300158 证券简称：振东制药 公告编号：2025-036 山西振东制药股份有限公司 关于公司重大仲裁事项履行完毕的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、本次仲裁的基本情况 （一）本次仲裁事项受理的基本情况 山西振东制药股份有限公司（以下简称"公司"、 ...

Group 1 - The core viewpoint of the article highlights the significant shift in the hair transplant industry with the introduction of a "taxi-style pricing scheme" by the National Medical Insurance Administration, moving away from the controversial fixed-price model to a per-follicle pricing system [1] - The hair transplant industry is currently facing challenges, as exemplified by Yonghe's financial performance, which has shown continuous losses since its IPO in 2021, with net profits of 120 million yuan, -85.85 million yuan, -546 million yuan, and -226 million yuan from 2021 to 2024 [1] - In contrast, the market for hair loss treatment drugs, particularly Minoxidil, is thriving, with Mandey's sales revenue projected to reach 1.337 billion yuan in 2024, reflecting a year-on-year growth of approximately 18.9% [1] Group 2 - Mandey has maintained a dominant market position, with over 50% market share in 2024, and has consistently held more than 70% market share from 2017 to 2022 [4] - The younger demographic is increasingly affected by hair loss, with over 2.5 billion people in China experiencing this issue, and 74.6% of them being born in the 1980s and 1990s [6] - The rise of Minoxidil products is attributed to the younger generation's preference for scientifically validated treatments, with Mandey and Dafeixin being the two leading brands in the market [8][12] Group 3 - Mandey has successfully penetrated both offline and online markets, establishing partnerships with over 2,000 public medical institutions and 90,000 retail pharmacies, while also achieving over 60% of its sales through e-commerce channels [10][11] - The introduction of new Minoxidil products, such as Mandey's foam formulation, has enhanced its market competitiveness, with the foam being the only approved formulation in China that minimizes skin irritation [9] - The overall hair health market in China has grown significantly, from 58.29 billion yuan in 2020 to 79.55 billion yuan in 2023, with projections to exceed 116.54 billion yuan by 2028 [20] Group 4 - The entry of new players and technological advancements in the Minoxidil market have led to increased competition, with companies like Lunan Pharmaceutical launching new products that challenge traditional brands like Dafeixin [24][25] - Dafeixin, despite its long-standing presence in the market, is facing challenges due to the emergence of new competitors and a decline in its market share, with a reported revenue of 2.971 billion yuan in 2024, down 18.06% year-on-year [26] - The article concludes that the Minoxidil market's explosive growth is driven by a younger, more educated consumer base that prioritizes effective and scientifically validated treatment options [27][28]

证券代码：300158 证券简称：振东制药 公告编号：2025-034 山西振东制药股份有限公司 关于股东股份解押及质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"或"本公司"）于 近日接到控股股东山西振东健康产业集团有限公司（以下简称"振 东集团"）通知，获悉其所持有的本公司部分股份做了解押及质押， 具体事项如下： 注：①上表中出现合计数与各分项数值总和不符，为四舍五入所致。 股东 名称 是否为 控股股 东 本次解除质 押股份数量 （股） 占其所持 股份比例 占公司 总股本 比例 起始日 解除日期 质权人 振东 集团 是 2,320,000 0.77% 0.23% 2024.6.21 2025.7.2 中国银行股份有限 公司长治市分行 振东 集团 是 4,000,000 1.32% 0.40% 2024.6.27 2025.7.2 中国银行股份有限 公司长治市分行 振东 集团 是 5,000,000 1.65% 0.50% 2024.5.14 2025.7.2 中国银行股份有限 公司长治市分行 振东 集团 ...

证券代码：300158 证券简称：振东制药 公告编号：2025-033 山西振东制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"或"本公司"） 分别于 2024 年 10 月 22 日、11 月 12 日召开公司第六届董事会第二 次会议、2024 年第二次临时股东大会，审议通过了《关于回购公司 股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购 公司部分股份，回购的股份将全部用于注销并减少公司注册资本。本 次用于回购股份的资金总额上限为人民币 10,000 万元，回购下限为 人民币 5,000 万元，回购价格不超过人民币 6.00 元/股（含本数）， 回购股份的实施期限为自公司股东大会审议通过本次回购股份方案 之日起不超过 12 个月。具体内容详见公司于 2024 年 10 月 24 日、2024 年 11 月 12 日刊登在巨潮资讯网（www.cninfo.com.cn）的相关公告。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股 份》等相关规定， ...

Industry Overview - The hair medical sector has shown significant activity recently, with the sector index reaching a new high as of June 10, 2023, driven by active stock performances from companies like Aoyang Health and Kanghui Medical [1] - The hair medical services can be divided into hair transplant services and medical hair care services, with hair transplant services currently dominating the market [1] - The growing trend of beauty economy and self-consumption is leading consumers to invest more time and money in hair health and aesthetics, which is expected to drive continuous growth in the hair medical industry [1] - According to Frost & Sullivan, the market size of hair medical services in China is projected to reach 138.1 billion yuan by 2030, with a CAGR of 22.3% from 2020 to 2030 [1] Market Dynamics - The medical hair care market is expected to grow rapidly due to the high frequency and repurchase characteristics of hair care services, with the "hair transplant and care" integration trend driving this growth [2] - By 2030, the medical hair care services are anticipated to account for 45.3% of the total hair medical services market in China, becoming a significant driver of industry development [2] Key Companies - Zhendong Pharmaceutical (300158): The company's main product, Dafeixin Minoxidil Solution, is the only topical medication approved by both the FDA and NMPA for treating hair loss [2] - Huilong Co., Ltd. (002556): The company offers hair growth and hair loss treatment products, including Zhi Zhi Hair Growth Tablets and Compound Ginseng Phenol Solution, which have national drug approval [2] - Kanghui Pharmaceutical (603139): The company has several drugs listed in the national medical insurance directory, including hair loss treatment tablets [3] - Aoyang Health: The company's subsidiary, Weien Medical Beauty, includes hair transplant services [4] - Tainkang (301263): The company is applying for a one-time import of raw materials for Baricitinib, which is under research for hair growth indications [4] - Kangyuan Pharmaceutical: The new hair loss treatment drug Minoxidil Tincture has completed registration verification and GMP compliance checks [4] - Langzi Co., Ltd. (002612): The company has medical beauty institutions that offer hair transplant-related services [5] - Huabang Health (002004): The company has a hair transplant center under Maan Skin, utilizing MN-FUE hair transplant technology for patient treatment [6]

Core Viewpoint - The announcement from the Shanxi Provincial Drug Administration details the results of GMP compliance inspections for 14 pharmaceutical manufacturing companies, indicating their adherence to national drug production standards [2]. Group 1: Inspection Results - The inspection results include companies such as China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd., which was inspected for hard capsule production of penicillin oral preparations [3]. - Other companies listed include Shanxi Huida Pharmaceutical Co., Ltd. and Shanxi Zhongyuan Pharmaceutical Co., Ltd., with various products ranging from oral solutions to traditional Chinese medicine pieces being evaluated for compliance [3][4]. - The inspections were conducted between January 16 and March 31, 2025, with all companies listed achieving compliance [3][4]. Group 2: Compliance Details - The compliance checks were based on the Drug Administration Law of the People's Republic of China and related regulations, ensuring that the inspected companies meet the required quality management standards [2]. - Specific products inspected include oral solutions, hard capsules, and raw materials, with detailed addresses and production lines provided for each company [3][4]. - The results signify a commitment to maintaining high standards in pharmaceutical production within the region, which is crucial for public health and safety [2].

证券代码：300158 证券简称：振东制药 公告编号：2025-032 （1）自可能对本公司证券及其衍生品种交易价格产生重大影响 的重大事项发生之日或者在决策过程中，至依法披露之日内； 山西振东制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"或"本公司"） 分别于 2024 年 10 月 22 日、11 月 12 日召开公司第六届董事会第二 次会议、2024 年第二次临时股东大会，审议通过了《关于回购公司 股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购 公司部分股份，回购的股份将全部用于注销并减少公司注册资本。本 次用于回购股份的资金总额上限为人民币 10,000 万元，回购下限为 人民币 5,000 万元，回购价格不超过人民币 6.00 元/股（含本数）， 回购股份的实施期限为自公司股东大会审议通过本次回购股份方案 之日起不超过 12 个月。具体内容详见公司于 2024 年 10 月 24 日、2024 年 11 月 12 日刊登在巨潮资讯网（www.cni ...

Group 1 - The hair medical concept sector increased by 2.20%, ranking 6th among concept sectors, with 16 stocks rising, including Huailong Co., which hit the daily limit, and Zhendong Pharmaceutical, *ST Meigu, and Baicheng Pharmaceutical showing notable gains of 7.32%, 4.81%, and 3.56% respectively [1][2] - The sector saw a net inflow of 142 million yuan from main funds, with 11 stocks receiving net inflows, led by Huailong Co. with a net inflow of 134 million yuan, followed by Baicheng Pharmaceutical, Shuiyang Co., and Minsheng Health with net inflows of 34.48 million yuan, 18.79 million yuan, and 11.22 million yuan respectively [2][3] - In terms of fund inflow ratios, Huailong Co., Baicheng Pharmaceutical, and International Medicine had the highest net inflow rates of 31.08%, 11.58%, and 6.12% respectively [3] Group 2 - The top gainers in the hair medical concept sector included Huailong Co. with a daily increase of 10.00% and a turnover rate of 7.90%, and Baicheng Pharmaceutical with a 3.56% increase and a turnover rate of 10.97% [3][4] - Conversely, the top decliners included Jiu Zhi Tang, Neng Te Ke Ji, and Kang Hui Pharmaceutical, which fell by 1.06%, 0.62%, and 0.36% respectively [1][4] - The overall performance of the hair medical concept sector reflects a positive trend in investor sentiment and capital inflow, indicating potential growth opportunities within the sector [2][3]